Showing 1-10 of 12 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Engineering B Cell–Targeted Microparticles to Induce Regulatory Immunity in Type 1 Diabetes | The University of North Carolina at Chapel Hill | Kristy Ainslie | Cures | 01-April-2026 to 31-March-2027 | $200.000,00 |
| ACTin1 for DD: Developing and Testing a Digital Single Session Acceptance and Commitment Therapy Intervention for Type 1 Diabetes Distress | Duke University | Max Roberts | Improving Lives | 01-April-2026 to 31-March-2029 | $241.710,00 |
| 3D bioprinted pancreatic tissue for beta cell replacement therapy | Wake Forest University Health Sciences | Amish Asthana | Cures | 01-March-2026 to 29-February-2028 | $599.990,14 |
| Advancing T1D Detection and Care Through AI | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-February-2025 to 31-May-2026 | $345.083,00 |
| Combining Arteriovenous Bundle and ECM-Based Biomaterial Technologies to Induce Potent Neovascularization Following Islet Transplantation | Wake Forest University Health Sciences | Giuseppe Orlando | Cures | 01-April-2025 to 31-March-2027 | $248.692,00 |
| JDRF Cures Patient Preference Study in Type 1 Diabetes | RTI International | Kelley Myers | Transportfolio | 01-July-2023 to 30-June-2026 | $831.600,00 |
| Adult T1D Detection at Geisinger | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-July-2023 to 31-May-2026 | $890.727,00 |
| JDRF-IQVIA Adult T1D Detection | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-October-2022 to 31-May-2026 | $953.780,00 |
| Development and Preclinical Assessment of a Biovascular Pancreas | Humacyte | Kaleb Naegeli | Cures | 01-April-2023 to 28-February-2027 | $863.333,00 |
| Using Genome Sequencing and Genetic Risk Scores to Identify Newborns with Serious Health Conditions: A Statewide Implementation Study | RTI International | Curt Scharfe | Cures | 01-December-2022 to 30-November-2025 | $3.356.049,93 |